SCHEMBL17487370

SCHEMBL17487370

CCCc1ccc(-c2ccc(OCc3cc(F)c(F)c(F)c3)c(F)c2F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.40
MAOB P27338 1/20 0.37
RARB P10826 1/20 0.36
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
FFAR1 O14842 2/20 0.35
GABRA1 P14867 3/20 0.34
GABRB2 P47870 3/20 0.34
ALOX5 P09917 1/20 0.34
MPL P40238 2/20 0.34
MRGPRX4 Q96LA9 1/20 0.34
PTGES O14684 1/20 0.33
GPR84 Q9NQS5 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17487748 0.95 RARB (0.37) FFAR4MAOBRARBNPC1TP53
SCHEMBL17487486 0.91 CNR1 (0.39) FFAR4MAOBNPC1TP53PKM
SCHEMBL17487891 0.90 RXRG (0.38) FFAR4MAOBFFAR1GABRA1GABRB2
SCHEMBL17487493 0.89 FFAR4 (0.36) FFAR4RARBNPC1TP53PKM
SCHEMBL12716851 0.89 FFAR4 (0.40) FFAR4RARBNPC1TP53PKM
SCHEMBL12736485 0.88 FFAR4 (0.42) FFAR4NPC1RAB9ASMN1; SMN2FFAR1
SCHEMBL12740939 0.88 FFAR4 (0.42) FFAR4NPC1RAB9ASMN1; SMN2FFAR1
SCHEMBL17487552 0.87 RARB (0.39) FFAR4RARBNPC1TP53PKM
SCHEMBL10302270 0.87 GABRA1 (0.40) FFAR4NPC1RAB9ASMN1; SMN2FFAR1
SCHEMBL17365798 0.87 MAOB (0.34) FFAR4MAOBFFAR1ALOX5PTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9441161-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-09-13 US disclosed
US-9441161-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-09-13 US disclosed
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-04 US disclosed
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD1, OCIAD2, PIEZO1 FFAR4 1903/4885MAOB 1419/4885RARB 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.